When SKHY insiders can sell
SK hynix Inc. · IPO prospectus filed 2026-07-10 · Single cliff · 90-day lock-up
That is the calendar date the clause computes to, counted from the prospectus date. It is the only date computable without knowing a future earnings date, which is why everything that could pull it earlier is printed below it on this page rather than folded into it.
The lock-up clause, in the issuer's words
Every other free lock-up calendar tells you 180 days and moves on. This is the actual sentence the date above was computed from, so that if the words do not support the number, the number is wrong and the filing is one click away.
…rean tax considerations relating to an investment in the ADSs, see "Certain Tax Considerations." Lock-up agreement We and certain of our affiliates may agree with the underwriters, subject to certain exceptions, not to sell, transfer or otherwise dispose of any ADSs, common shares or similar securities for a period of 90 days after the date of this prospectus. See "Shares Eligible for Future Sale" and "Underwriting" for more information. Risk factors See "Risk Factors" beginning on page 18 and the other information included in this prospectus for a discussion of factors you should consider before deciding to invest in the ADSs. Payment and settlement The underwriters expect to deliver the ADSs against payment therefor through the facilities of the Depository Trust Company ("DTC") on July 14, 2026, which will be the third business day following the pricing of the ADSs.
Where the share count comes from
The prospectus never prints the number of shares coming free, and nothing in it lets the figure be derived. That is why this deal carries no flow math.
Exceptions written into the lock-up (2)
Each of these is a route by which SKHY shares can move before 2026-10-08. The 10b5-1 carve-out is the one worth reading twice: it lets insiders put a selling plan in place during the lock-up, so the first sales can be automatic and immediate rather than discretionary and later.
- pledge as collateral
- option exercise or RSU settlement
…0,720 Selling and administrative expenses 242,739 249,368 250,180 Research and development expenses and others 581,282 590,117 669,550 W 12,663,516 W 11,535,635 W 12,730,450 (3) Certain property, plant and equipment are pledged as collaterals for borrowings of the Group as of December 31, 2025 (See note 32). (4) The Group capitalized borrowing costs amounting to W 249,760 million (2024: W 202,995 million and 2023: W 136,622 million) on qualifying assets during the year ended December 31, 2025. Borrowing costs were calculated using a capitalization rate of 3.91% (2024: 6.32% and 2023: 4.34%) for the year ended December 31, 2025. (5) The Group provides certain property, plant, and equipment as operating leases.
…s offering: is based upon 711,075,500 common shares outstanding as of the date of this prospectus; and excludes 1,626,865 common shares held by us as treasury shares, including 138,685 common shares deliverable upon the exercise of stock options (as described in "Management — Compensation — Stock Options"), outstanding as of the date of this prospectus. 13 Table of Contents SUMMARY FINANCIAL AND OTHER INFORMATION The following tables set forth, for the periods and as of the dates indicated, our summary financial and operating data. The financial information presented in this prospectus has been derived from our Audited Financial Sta…
What we could not establish
SKHY is read but not publishable: the prospectus does not state how many shares come free. So there is no absorb-day figure on this page and no call, and there will not be one until the number exists in a filing.
The common case is a prospectus that says "substantially all" of the locked shares become eligible for sale without ever printing a count. The clause above is quoted in full so you can see that for yourself. An estimate presented with a filing link beside it would read as a filing figure, and that is worse than an admission — it is the one failure mode a reader cannot detect.
How this reading of SKHY could be wrong
The lock-up period is restated 4 times in this prospectus. Issuers repeat the clause on the cover, in the summary, in the risk factors and in the underwriting section, and the wording is not always identical. The parser resolved them to one period; if a reader finds a restatement that disagrees, the quote above is the one it used.
The volume is a vendor's, not ours. SKHY is not in our own price table, so average daily volume comes from yahoo-finance2 daily bars (symbol not in our price table). Vendor bars for recently listed symbols are the ones most likely to be wrong.
Only 20 sessions of volume history. This is a recent IPO, and early volume is dominated by the offering itself. An average over 20 sessions of a stock that has barely traded is the weakest input on the page, and absorb days inherits every bit of that weakness.
The parser can misread a filing. That is why every number here is printed next to the words it came from. Earlier versions of this parser read the underwriters' 30-day over-allotment window as a 30-day lock-up on five deals, and double-counted one issuer's share total because the offering summary appears on both the cover and in the summary section.
Also unlocking in 2026-10 (10)
Lock-ups cluster, because IPOs cluster: these priced in the same window as SKHY and come free in the same month. Several heavy releases landing together is a different situation from one.
| Deal | Expiry | Shares free | Absorb days |
|---|---|---|---|
| ARXS Arxis, Inc. | 2026-10-13 | 23.2M | 24.0 sessions |
| ALMR Alamar Biosciences, Inc. | 2026-10-14 | 55.3M | 68.6 sessions |
| KLRA Kailera Therapeutics, Inc. | 2026-10-14 | 84.6M | 83.0 sessions |
| AVEX AEVEX Corp. | 2026-10-17 | 95.6M | 34.5 sessions |
| ELMT Elmet Group Co. | 2026-10-20 | 20.3M | 43.0 sessions |
| YSWY Yesway, Inc. | 2026-10-20 | — | — |
| XE X-Energy, Inc. | 2026-10-24 | 348.1M | 54.2 sessions |
| AVLN Avalyn Pharma Inc. | 2026-10-27 | 25.1M | 60.1 sessions |
| SPTX Seaport Therapeutics, Inc. | 2026-10-28 | 38.9M | 160 sessions |
| COAG Hemab Therapeutics Holdings, Inc. | 2026-10-28 | — | — |
Learn to read these clauses yourself
The flow arithmetic on this page — shares unlocking divided by average daily volume, and why the clause has to be read rather than assumed — taught step by step, free.
Radar built 2026-11-07 from EDGAR full-text search over 424B4 filings · all 80 parsed lock-ups and the scoreboard · SKHY's prospectus on EDGAR · what funds carried these companies at before listing